SCHEMBL3574069

SCHEMBL3574069

Cc1cccc(OC[C@H](CCOc2ccccc2)NC(=O)O)c1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.53
DRD2 P14416 1/20 0.52
DRD4 P21917 1/20 0.52
MAPK1 P28482 2/20 0.49
KDM4E B2RXH2 1/20 0.49
HPGD P15428 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
OPRM1 P35372 1/20 0.47
OPRD1 P41143 1/20 0.47
ALOX5 P09917 1/20 0.47
PPARG P37231 1/20 0.47
PPARA Q07869 1/20 0.47
POLB P06746 1/20 0.47
ADRB2 P07550 1/20 0.46
ADRB1 P08588 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3585190 0.91 SMN1; SMN2 (0.52) SMN1; SMN2DRD2DRD4MAPK1ADRB2
SCHEMBL13316685 0.90 SMN1; SMN2 (0.49) SMN1; SMN2DRD2DRD4MAPK1KDM4E
SCHEMBL3566335 0.84 SMN1; SMN2 (0.51) SMN1; SMN2MAPK1KDM4EL3MBTL1POLB
SCHEMBL3576228 0.84 ALDH1A1 (0.43) SMN1; SMN2DRD2DRD4MAPK1KDM4E
SCHEMBL3580415 0.80 KMT2A (0.52) SMN1; SMN2MAPK1KDM4EHPGDADRB2
SCHEMBL3570361 0.78 TDP1 (0.48) SMN1; SMN2HPGDTDP1L3MBTL1PPARG
SCHEMBL3581797 0.77 DRD2 (0.55) SMN1; SMN2DRD2DRD4TDP1L3MBTL1
SCHEMBL3578459 0.76 MEN1 (0.44) SMN1; SMN2MAPK1HPGDL3MBTL1OPRM1
SCHEMBL10876442 0.76 SMN1; SMN2 (0.52) SMN1; SMN2DRD2DRD4MAPK1KDM4E
SCHEMBL2063136 0.75 DRD2 (0.72) SMN1; SMN2DRD2DRD4MAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728005-B2 Ether derivative AJINOMOTO CO., INC. (JP) 2010-06-01 US disclosed
US-20060270693-A1 Ether derivative AJINOMOTO CO., INC. (JP) 2006-11-30 US disclosed
EP-1679296-A1 ETHER DERIVATIVE Ajinomoto Co., Inc. (JP) 2006-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270693-A1 Ether derivative UROD, IL5, IL17A SMN1; SMN2 891/4885DRD2 1532/4885DRD4 2154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.